Nykode Therapeutics (Vaccibody) småprat (NYKD)

[Boms]

Tidenes tynneste Radium, med null nyhetsverdi - dessverre.

Kort oppsummert om NYKD, startet studie i USA, kan være registreringstudie, vet ikke når den er ferdig men kjempespennende.

[TekBot]

Nykode Therapeutics ASA - Notice of Annual General Meeting

Oslo, Norway, April 25, 2024 – The Board of Directors of Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, hereby calls for the Annual General Meeting to be held at meeting room FORUM - Building H, Floor 0 in Gaustadalléen 21, Oslo, Norway at 10:00 CET on May 16, 2024.

All documents regarding the Annual General Meeting are available at the Company’s website: www.nykode.com/investors/corporate-governance/annual-general-meeting/
…

Vis børsmeldingen

For further information, please see the Company’s website or contact the Company at IR@nykode.com

About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a focus on the treatment of cancer and autoimmune diseases. Nykode’s modular vaccine technology specifically targets antigens to antigen presenting cells (APC), which have been shown to induce a broad, strong and long-lasting antigen specific immune response in cancer, which correlates with clinical responses.

Nykode’s lead product candidates are VB10.16, a therapeutic vaccine for the treatment of HPV16 induced malignancies which demonstrated favorable safety and efficacy results from its Phase 2 trial for the treatment of cervical cancer. VB10.16 is being expanded into multiple trials for treatment of head and neck cancer and cervical cancer. VB10.NEO, an individualized cancer neoantigen vaccine, is exclusively out-licensed to Genentech, a member of the Roche Group.

The Company’s partnerships include Genentech within oncology and a multi-target collaboration with Regeneron in oncology and infectious diseases.

Nykode is also utilizing its APC-targeted technology to create an inverse vaccine platform for the potential use in autoimmune disorders, organ transplant rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics’ shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics can be found at http://www.nykode.com.

Contact for Nykode Therapeutics ASA:
Alexandra Deschner, Head of IR
Nykode Therapeutics ASA
IR@nykode.com

Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway

Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company’s current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

This information is subject to the disclosure requirements pursuant to sections 5-12 of the Norwegian Securities Trading Act.

Kilde

[Boms]

Kanskje ikke en kioskvelter av en nyhet, men litt interessant for oss som håper på noe positivt :

[beholdning]

Tester historisk kreftsprøyte: – Kan bli livreddende

[safin]

analytiker ser tegn til friskmelding av bioteksektoren

[Boms]

Det står ikke noe spesifikt om Nykode i artikkelen, det er bare basert på at biotek indeksen i USA igjen har begynt å stige. I for seg interessant det men lite matnyttig i forhold til selskapet.

[the1nonly]

@Boms

det er bare basert på at biotek indeksen i USA igjen har begynt å stige

Synes Holom vinkler dette LITT spesielt. Riktignok har XBI steget fra Oct 23 - som da var helt nede på 2016 nivå(!). Men siste to mnd. er XBI minus 20% og i en sterk nedadgående trend. Det er ikke et tegn på friskmelding av biotek sektoren.

[Pk2k]

Holom er jo helt blåst da

[Fornybar]

https://twitter.com/fornybarbio/status/1784816790008164693?t=IbNVBojdglPO17UB8XP7xQ&s=19

Nykode kommer med nye prekliniske data om noen dager.

[Roc]

Prekliniske……når kommer kliniske, er vel klinikk som betyr noe…

[Fornybar]

Strengt tatt et NEO solgt, så kliniske data derifra er added risk mot de andre programmene og andre utlisensieringer. Strategisk vil det kanskje være greit å ha kontroll over dataene som publiseres (med mindre de er veldig gode da)

[Boms]

Ettersom dette bare er pre-kliniske data, tipper jeg at dette forsøk som viser bruk på både mRNA og DNA vaksiner. Hintet jeg baserer det på ligger i tittelen på foredraget som ikke kom med i den første posten.

[safin]

Något som fått med sig vad som blev presenterat idag?

[Boms]

Denne ligger nå ute på deres webside:

240501_NeoAg-summit_Europe_Fredriksen-1.pdf

Ser ut som om det er kun fokus på NEO vaksinen, og en blanding av kliniske resultater for DNA vaksinen og pre-klinisk for en mRNA vaksine. Noen dyp tolkning skal nok andre med bedre utdannelse innen faget enn meg gjøre.

[beholdning]

[safin]

Nykode Therapeutics følger fast-to-market-strategi for HPV16-målrettet kreftvaksine 2. mai 2024 | Catherine Shaffer NEW YORK – Nykode Therapeutics forfølger en rask-til-markedsstrategi for sin HPV16-målrettede vaksine mot avansert livmorhalskreft, men firmaet mener at deres vaksiner potensielt kan behandle pre-malign til sent stadium sykdom i flere tumortyper. https://www.precisionmedicineonline.com/precision-oncology/nykode-therapeutics-pursuing-fast-market-strategy-hpv16-targeted-cancer-vaccine.

[TekBot]

Nykode Therapeutics – invitation to Q1 2024 financial results presentation

Oslo, Norway, May 7, 2024 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced it will release its first quarter 2024 financial results before the opening of financial markets on Tuesday, May 14, 2024.

The Company will host a subsequent webcast presentation to review the financial and operating results. A question-and-answer session will follow.
…

Vis børsmeldingen

First Quarter 2024 Webcast:

Date: Tuesday, May 14, 2024
Time: 4 p.m. CET / 10 a.m. ET
Webcast: Nykode Therapeutics – Q1 2024 Financial Results Presentation - 1670178

The financial report, as well as a live and archived webcast of the presentation, can be accessed in the Financial Reports and Presentations section of the Company’s website: https://nykode.com/investors/financial-reports-and-presentations.

About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a focus on the treatment of cancer and autoimmune diseases. Nykode’s modular vaccine technology specifically targets antigens to antigen presenting cells (APC), which have been shown to induce a broad, strong and long-lasting antigen specific immune response in cancer, which correlates with clinical responses.

Nykode’s lead product candidates are VB10.16, a therapeutic vaccine for the treatment of HPV16 induced malignancies which demonstrated favorable safety and efficacy results from its Phase 2 trial for the treatment of cervical cancer. VB10.16 is being expanded into multiple trials for treatment of head and neck cancer and cervical cancer. VB10.NEO, an individualized cancer neoantigen vaccine, is exclusively out-licensed to Genentech, a member of the Roche Group.

The Company’s partnerships include Genentech within oncology and a multi-target collaboration with Regeneron in oncology and infectious diseases.

Nykode is also utilizing its APC-targeted technology to create an inverse vaccine platform for the potential use in autoimmune disorders, organ transplant rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics’ shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics can be found at http://www.nykode.com.

Contact:
Alexandra Deschner, Head of IR
Nykode Therapeutics ASA
IR@nykode.com

Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway

Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company’s current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Kilde

[beholdning]

12.05.24 – Nykode Therapeutics – Aksjefrue.no

NYKD sett fra TA perspektiv

[beholdning]

Vaksine gir nytt håp i kampen mot aggressiv hjernekreft

Nykd nevnt i slutten av artikkelen.

[TekBot]

Nykode Therapeutics - Quarterly report Q1 2024

Oslo, Norway, May 14, 2024 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced its unaudited financial results for the first quarter of 2024.

The financial report can be accessed in the Investors section of the Company’s website: https://nykode.com/investors/financial-reports-and-presentations.
…

Vis børsmeldingen

The Company will host a webcast presentation at 4 p.m. CET / 10 a.m. ET. A live and archived webcast of the presentation can be accessed in the Investors section of the Company’s website and on the following link: Nykode Therapeutics – Q1 2024 Financial Results Presentation - 1670178

About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a focus on the treatment of cancer and autoimmune diseases. Nykode’s modular vaccine technology specifically targets antigens to antigen presenting cells (APC), which have been shown to induce a broad, strong and long-lasting antigen specific immune response in cancer, which correlates with clinical responses.

Nykode’s lead product candidates are VB10.16, a therapeutic vaccine for the treatment of HPV16 induced malignancies which demonstrated favorable safety and efficacy results from its Phase 2 trial for the treatment of cervical cancer. VB10.16 is being expanded into multiple trials for treatment of head and neck cancer and cervical cancer. VB10.NEO, an individualized cancer neoantigen vaccine, is exclusively out-licensed to Genentech, a member of the Roche Group.

The Company’s partnerships include Genentech within oncology and a multi-target collaboration with Regeneron in oncology and infectious diseases.

Nykode is also utilizing its APC-targeted technology to create an inverse vaccine platform for the potential use in autoimmune disorders, organ transplant rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics’ shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics can be found at http://www.nykode.com.

Contact:
Alexandra Deschner, Head of IR
Nykode Therapeutics ASA
IR@nykode.com

Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway

Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company’s current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Kilde